Evaluating Five-Year Efficacy Outcomes in EMPOWER-LUNG 1
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Video content above is prompted by the following:
- What is the current five-year prognosis for advanced NSCLC in terms of overall survival and progression-free survival?
- How do the reported OS and PFS outcomes compare with other PD-1/PD-L1 inhibitors in the setting of advanced NSCLC?
- How does this new five-year data impact clinical decision-making for cemiplimab as a first-line treatment for patients with advanced NSCLC?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
